Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy
Achillion Pharmaceuticals announced an agreement with Imperial College London to conduct a natural history study of C3 glomerulopathy, a rare renal disorder which includes dense deposit disease and C3 glomerulonephritis. C3G affects an estimated 8,000 people across Europe and the U.S. February 28, 2017